These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37792394)
1. Effects of the Acute and Chronic Administration of Cannabidiol on Cognition in Humans and Animals: A Systematic Review. Bomfim AJL; Zuze SMF; Fabrício DM; Pessoa RMP; Crippa JAS; Chagas MHN Cannabis Cannabinoid Res; 2023 Dec; 8(6):955-973. PubMed ID: 37792394 [No Abstract] [Full Text] [Related]
2. The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study. Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC Cannabis Cannabinoid Res; 2024 Feb; 9(1):230-240. PubMed ID: 35881851 [No Abstract] [Full Text] [Related]
3. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder. Lees R; Hines LA; Hindocha C; Baio G; Shaban NDC; Stothart G; Mofeez A; Morgan CJA; Curran HV; Freeman TP Psychopharmacology (Berl); 2023 Feb; 240(2):337-346. PubMed ID: 36598543 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Osborne AL; Solowij N; Weston-Green K Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751 [TBL] [Abstract][Full Text] [Related]
5. A systematic review of cannabidiol trials in neurodevelopmental disorders. Parrella NF; Hill AT; Enticott PG; Barhoun P; Bower IS; Ford TC Pharmacol Biochem Behav; 2023 Sep; 230():173607. PubMed ID: 37543051 [TBL] [Abstract][Full Text] [Related]
6. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol. Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233 [TBL] [Abstract][Full Text] [Related]
7. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533 [TBL] [Abstract][Full Text] [Related]
8. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Martin RC; Gaston TE; Thompson M; Ampah SB; Cutter G; Bebin EM; Szaflarski JP Epilepsy Behav; 2019 Aug; 97():105-110. PubMed ID: 31220785 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations. Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346 [No Abstract] [Full Text] [Related]
10. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders. Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506 [TBL] [Abstract][Full Text] [Related]
11. Effects of daily Δ Withey SL; Kangas BD; Charles S; Gumbert AB; Eisold JE; George SR; Bergman J; Madras BK Drug Alcohol Depend; 2021 Apr; 221():108629. PubMed ID: 33640678 [TBL] [Abstract][Full Text] [Related]
12. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Elsaid S; Kloiber S; Le Foll B Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406 [TBL] [Abstract][Full Text] [Related]
13. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. Metternich B; Wagner K; Geiger MJ; Hirsch M; Schulze-Bonhage A; Klotz KA Epilepsy Behav; 2021 Jan; 114(Pt A):107558. PubMed ID: 33246899 [TBL] [Abstract][Full Text] [Related]
14. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290 [TBL] [Abstract][Full Text] [Related]
15. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068 [TBL] [Abstract][Full Text] [Related]
16. Subjective, behavioral and neurobiological effects of cannabis and cannabinoids in social anxiety. Rosário BDA; Lemes JA; de Lima MP; Ribeiro DA; Viana MB Rev Neurosci; 2024 Feb; 35(2):197-211. PubMed ID: 37812748 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review. Rodrigues LA; Caroba MES; Taba FK; Filev R; Gallassi AD Pharmacol Biochem Behav; 2020 Sep; 196():172982. PubMed ID: 32645315 [TBL] [Abstract][Full Text] [Related]
18. Effects of oral Δ9-tetrahydrocannabinol and cannabidiol combinations on a sustained attention task in rats. Moore CF; Davis CM; Sempio C; Klawitter J; Christians U; Weerts EM Exp Clin Psychopharmacol; 2023 Oct; 31(5):881-887. PubMed ID: 36634015 [TBL] [Abstract][Full Text] [Related]
19. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447 [TBL] [Abstract][Full Text] [Related]